Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRLX101 with Chemoradiotherapy in Rectal Cancer
NCT02010567Phase 2Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 2013
- Primary completion
- Sep 2016
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CRLX101 in rectal cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Started Dec 2013; status: terminated.
02
Drugs
CRLX101
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02010567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02010567.